Abstract
The New Zealand Obese (NZO) mouse is one of the most thoroughly investigated polygenic models for the human metabolic syndrome and type 2 diabetes. It presents the main characteristics of the disease complex, including early-onset obesity, insulin resistance, dyslipidemia, and hypertension. As a consequence of this syndrome, a combination of lipotoxicity and glucotoxicity produces beta-cell failure and apoptosis resulting in hypoinsulinemia and diabetic hyperglycemia. With NZO as a breeding partner, several adipogenic and diabetogenic gene variants have been identified by hypothesis-free positional cloning (Tbc1d1, Zfp69) or by combining genetic screens and candidate gene approaches (Pctp, Abcg1, Nmur2, Lepr). This chapter summarizes the present knowledge of the NZO strain and describes its pathophysiology as well as the known underlying genetic defects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Leiter EH (2009) Selecting the “right” mouse model for metabolic syndrome and type 2 diabetes research. Methods Mol Biol 560:1–17
Bielschowsky M, Bielschowsky F (1953) A new strain of mice with hereditary obesity. Proc Univ Otago Med School 31:29–31
Bielschowsky M, Goodall CM (1970) Origin of inbred NZ mouse strains. Cancer Res 30:834–836
Bielschowsky F, Bielschowsky M (1956) The New Zealand strain of obese mice; their response to stilboestrol and to insulin. Aust J Exp Biol Med Sci 34:181–198
Ortlepp JR et al (2000) A metabolic syndrome of hypertension, hyperinsulinaemia and hypercholesterolaemia in the New Zealand obese mouse. Eur J Clin Invest 30:195–202
Festing M (1997) Inbred strains of mice. Mouse Genome 95:519–686
Koza RA et al (2004) Contributions of dysregulated energy metabolism to type 2 diabetes development in NZO/H1Lt mice with polygenic obesity. Metabolism 53:799–808
Herberg L, Coleman DL (1977) Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26:59–99
Chankiewitz E (2005) Beiträge zur Charakterisierung eines diabetischen Tiermodells: die New Zealand obese-Maus (NZO). In: Medizinische Fakultät. Martin-Luther-Universität, Halle-Wittenberg, p 79
Radavelli-Bagatini S et al (2011) The New Zealand obese mouse model of obesity insulin resistance and poor breeding performance: evaluation of ovarian structure and function. J Endocrinol 209(3):307–315
Crofford OB, Davis CK Jr (1965) Growth characteristics, glucose tolerance and insulin sensitivity of New Zealand obese mice. Metabolism 14:271–280
Ackert-Bicknell C et al (2011) Aging study: bone mineral density and body composition of 32 inbred strains of mice. Mouse Phenome Database web site, The Jackson Laboratory, Bar Harbor, ME. http://phenome.jax.org
Plum L et al (2002) Characterisation of the mouse diabetes susceptibility locus Nidd/SJL: islet cell destruction, interaction with the obesity QTL Nob1, and effect of dietary fat. Diabetologia 45:823–830
Mirhashemi F et al (2011) Diet dependence of diabetes in the New Zealand obese (NZO) mouse: total fat, but not fat quality or sucrose accelerates and aggravates diabetes. Exp Clin Endocrinol Diabetes 119:167–171
Jürgens HS et al (2006) Hyperphagia, lower body temperature, and reduced running wheel activity precede development of morbid obesity in New Zealand obese mice. Physiol Genomics 25:234–241
Igel M et al (1997) Hyperleptinemia, leptin resistance, and polymorphic leptin receptor in the New Zealand obese mouse. Endocrinology 138:4234–4239
Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770
Halaas JL et al (1997) Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A 94:8878–8883
Ferreras L et al (1994) Early decrease in GLUT4 protein levels in brown adipose tissue of New Zealand obese mice. Int J Obes Relat Metab Disord 18:760–765
Subrahmanyam K (1960) Metabolism in the New Zealand strain of obese mice. Biochem J 76:548–556
Larkins RG (1971) Plasma growth hormone in the New Zealand obese mouse. Diabetologia 7:302–307
Huchzermeyer H, Rudorff KH, Staib W (1973) (Experimental studies on the problem of insulin resistance in adipositas and diabetes mellitus, with the aid of New Zealand obese mice. Pathogenesis of the obese-hyperglycaemic syndrome (author’s transl)). Z Klin Chem Klin Biochem 11:249–256
Jürgens HS et al (2007) Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction. Diabetologia 50:1481–1489
Veroni MC, Proietto J, Larkins RG (1991) Evolution of insulin resistance in New Zealand obese mice. Diabetes 40:1480–1487
Rudorff KH et al (1970) The influence of insulin on the alanine gluconeogenesis in isolated perfused livers of New Zealand obese mice. Eur J Biochem 16:481–486
Sneyd JG (1964) Pancreatic and serum insulin in the New Zealand strain of obese mice. J Endocrinol 28:163–172
Stauffacher W, Renold AE (1969) Effect of insulin in vivo on diaphragm and adipose tissue of obese mice. Am J Physiol 216:98–105
Fesus G et al (2007) Adiponectin is a novel humoral vasodilator. Cardiovasc Res 75:719–727
Joost HG (2010) The genetic basis of obesity and type 2 diabetes: lessons from the New Zealand obese mouse, a polygenic model of the metabolic syndrome. Results Probl Cell Differ 52:1–11
Leiter EH et al (1998) NIDDM genes in mice: deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes 47:1287–1295
Plum L et al (2000) Type 2 diabetes-like hyperglycemia in a backcross model of NZO and SJL mice: characterization of a susceptibility locus on chromosome 4 and its relation with obesity. Diabetes 49:1590–1596
Bray GA, York DA (1971) Genetically transmitted obesity in rodents. Physiol Rev 51:598–646
Stauffacher W et al (1967) Measurements of insulin activities in pancreas and serum of mice with spontaneous (“Obese” and “New Zealand Obese”) and induced (Goldthioglucose) obesity and hyperglycemia, with considerations on the pathogenesis of the spontaneous syndrome. Diabetologia 3:230–237
Haskell BD et al (2002) The diabetes-prone NZO/HlLt strain. I. Immunophenotypic comparison to the related NZB/BlNJ and NZW/LacJ strains. Lab Invest 82:833–842
Kluth O et al (2011) Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure. Diabetologia 54:605–616
Cameron DP, Opat F, Insch S (1974) Studies of immunoreactive insulin secretion in NZO mice in vivo. Diabetologia 10(suppl):649–654
Lange C et al (2006) The diabetes-prone NZO/Hl strain. Proliferation capacity of beta cells in hyperinsulinemia and hyperglycemia. Arch Physiol Biochem 112:49–58
Junger E et al (2002) The diabetes-prone NZO/Hl strain. II. Pancreatic immunopathology. Lab Invest 82:843–853
Gates RJ et al (1972) Return to normal of blood-glucose, plasma-insulin, and weight gain in New Zealand obese mice after implantation of islets of Langerhans. Lancet 2:567–570
Gates RJ et al (1972) Studies on implanted islets of Langerhans: normalization of blood glucose concentration, blood insulin concentration and weight gain in New Zealand obese mice. Biochem J 130:26P–27P
Gates RJ, Hunt MI, Lazarus NR (1974) Further studies on the amelioration of the characteristics of New Zealand obese (NZO) mice following implantation of islets of Langerhans. Diabetologia 10:401–406
Leiter EH, Chapman HD, Falany CN (1991) Synergism of obesity genes with hepatic steroid sulfotransferases to mediate diabetes in mice. Diabetes 40:1360–1363
Tsukahara C et al (2004) Blood pressure in 15 inbred mouse strains and its lack of relation with obesity and insulin resistance in the progeny of an NZO/HILtJ x C3H/HeJ intercross. Mamm Genome 15:943–950
Leiter EH, Reifsnyder PC (2004) Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes. Diabetes 53(suppl 1):S4–S11
Brosius FC III et al (2009) Mouse models of diabetic nephropathy. J Am Soc Nephrol 20:2503–2512
Brennick MJ et al (2009) Altered upper airway and soft tissue structures in the New Zealand obese mouse. Am J Respir Crit Care Med 179:158–169
Goodall CM et al (1973) Oncological and survival reference data for NZO-B1 inbred mice. Lab Anim 7:65–71
Clee SM et al (2006) Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat Genet 38:688–693
Dokmanovic-Chouinard M et al (2008) Positional cloning of “Lisch-Like”, a candidate modifier of susceptibility to type 2 diabetes in mice. PLoS Genet 4:e1000137
Taylor BA et al (2001) Multiple obesity QTLs identified in an intercross between the NZO (New Zealand obese) and the SM (small) mouse strains. Mamm Genome 12:95–103
Giesen K et al (2003) Diet-dependent obesity and hypercholesterolemia in the New Zealand obese mouse: identification of a quantitative trait locus for elevated serum cholesterol on the distal mouse chromosome 5. Biochem Biophys Res Commun 304:812–817
Pan HJ et al (2006) A polymorphism in New Zealand inbred mouse strains that inactivates phosphatidylcholine transfer protein. FEBS Lett 580:5953–5958
Schmolz K et al (2007) Role of neuromedin-U in the central control of feeding behavior: a variant of the neuromedin-U receptor 2 contributes to hyperphagia in the New Zealand obese mouse. Obes Metab Milan 3:28–37
Buchmann J et al (2007) Ablation of the cholesterol transporter adenosine triphosphate-binding cassette transporter G1 reduces adipose cell size and protects against diet-induced obesity. Endocrinology 148:1561–1573
Schulz N et al (2011) Role of medium- and short-chain L-3-hydroxyacyl-CoA dehydrogenase in the regulation of body weight and thermogenesis. Endocrinology 152:4641–4651
Reifsnyder PC, Leiter EH (2002) Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes 51:825–832
Pan HJ et al (2005) Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes. Diabetes 54:1854–1862
Leiter EH et al (2006) Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes. Endocrinology 147:919–926
Pan HJ et al (2006) Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. Vascul Pharmacol 45:65–71
Kluge R et al (2000) Quantitative trait loci for obesity and insulin resistance (Nob1, Nob2) and their interaction with the leptin receptor allele (LeprA720T/T1044I) in New Zealand obese mice. Diabetologia 43:1565–1572
Chadt A et al (2008) Tbc1d1 mutation in lean mouse strain confers leanness and protects from diet-induced obesity. Nat Genet 40:1354–1359
Meyre D et al (2008) R125W coding variant in TBC1D1 confers risk for familial obesity and contributes to linkage on chromosome 4p14 in the French population. Hum Mol Genet 17:1798–1802
Stone S et al (2006) TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. Hum Mol Genet 15:2709–2720
Stewart TP, Kim HY, Saxton AM et al (2010) Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice. BMC Genomics 11:713
Scherneck S et al (2009) Positional cloning of zinc finger domain transcription factor Zfp69, a candidate gene for obesity-associated diabetes contributed by mouse locus Nidd/SJL. PLoS Genet 5:e1000541
Scherneck S et al (2010) Role of zinc finger transcription factor zfp69 in body fat storage and diabetes susceptibility of mice. Results Probl Cell Differ 52:57–68
Vogel H et al (2009) Characterization of Nob3, a major quantitative trait locus for obesity and hyperglycemia on mouse chromosome 1. Physiol Genomics 38:226–232
Scherneck S (2007) Identifizierung eines diabetogenen Allels im Suszeptibilitätslocus Nidd/SJL der Maus. Department of Pharmacology (German Institute of Human Nutrition), Universität Potsdam, Potsdam, p 85
Reifsnyder PC, Churchill G, Leiter EH (2000) Maternal environment and genotype interact to establish diabesity in mice. Genome Res 10:1568–1578
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kluge, R., Scherneck, S., Schürmann, A., Joost, HG. (2012). Pathophysiology and Genetics of Obesity and Diabetes in the New Zealand Obese Mouse: A Model of the Human Metabolic Syndrome. In: Joost, HG., Al-Hasani, H., Schürmann, A. (eds) Animal Models in Diabetes Research. Methods in Molecular Biology, vol 933. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-068-7_5
Download citation
DOI: https://doi.org/10.1007/978-1-62703-068-7_5
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-067-0
Online ISBN: 978-1-62703-068-7
eBook Packages: Springer Protocols